Table 2.
Unadjusted Outcomes in Patients Before and After the HCPP Adoption at Phase 1 Adopter, Phase 2 Adopter, and Non-Adopter Sites
| Phase 1 adopter vs. non-adopter | Phase 2 adopter vs. non-adopter | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1 adopter | Non-adopter | Phase 2 adopter | Non-adopter | |||||||
| Pre period | Post period | Pre period | Post Period | Pre period | Post Period | Pre period | Post Period | |||
| Entire period | Pilot | Main-tenance | ||||||||
| Process measures | ||||||||||
| BP rechecka | 24.9% | 51.1% | 39.4% | 59.5% | 16.0% | 17.7% | 11.6% | 34.8% | 15.9% | 19.5% |
| 90-day follow-upb | 68.2% | 65.4% | 70.1% | 61.8% | 67% | 63% | 80% | 72% | 67% | 59% |
| Clinical outcomes | ||||||||||
| BP control | 59.9% | 65.6% | 64.0% | 66.8% | 65.8% | 68.9% | 60.3% | 65.2% | 66.8% | 69.2% |
| Non-severely elevated BP | 84.3% | 86.3% | 85.7% | 86.8% | 89.9% | 90.4% | 83.6% | 85.4% | 90.1% | 90.4% |
| Exploratory outcome | ||||||||||
| Medication advancementc | 28.6% | 32.5% | 22.8% | 23.0% | ||||||
aBP recheck, same-day blood pressure (BP) recheck among those with an elevated BP measurement
bAt least one BP measurement in the same site within 90 days of a confirmed elevated BP; the post-period ends in December 2018 for this outcome to allow for a 90-day follow-up period.
cOnly evaluated among the subset of patients with medication data within a year before and after the adoption of the HCPP